HBM Holdings Limited (HKG:2142)

Market Cap	6.37B
Revenue (ttm)	295.94M
Net Income (ttm)	21.58M
Shares Out	802.33M
EPS (ttm)	0.03
PE Ratio	282.69
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,442,000
Average Volume	12,534,692
Open	8.08
Previous Close	7.94
Day's Range	7.93 - 8.34
52-Week Range	1.06 - 10.00
Beta	1.82
RSI	55.62
Earnings Date	Mar 27, 2025

About HBM Holdings

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The company has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 183
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2142

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD